AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: blood

newssourceFORcompanyinformationcontent1releasesmarket

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders...

Vast majority of patients dosed completed the full 12-week study

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational...

Herbalgy Trophy Wraps Up with a Thrilling 1-0 Victory Tottenham for Over Arsenal

Football Fever Grips Hong Kong as nearly 50,000 Fans Pack Kai Tak Download high-resolution images:  HONG KONG, Aug. 1, 2025 /PRNewswire/ -- The Herbalgy Trophy: Arsenal vs...

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). The supplemental application for the additional indication was selected for review under Project Orbis.

Meridian and the Centene Foundation Announce $1 Million Grant to the Food Bank Council of Michigan

The partnership aims to expand access to fresh food and enhance health outcomes in rural southwest Michigan food deserts DETROIT, July 31, 2025 /PRNewswire/ -- Meridian...

Expert insights about the impact of plastics on health, combating medical misinformation, and implementing AI in the clinic draw nearly 16,500 attendees to ADLM...

CHICAGO, July 31, 2025 /PRNewswire/ -- The Association for Diagnostics & Laboratory Medicine (ADLM, formerly AACC), welcomed thousands of laboratory experts to ADLM 2025...

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results

PL BioScience Announces Major Site Expansion

AACHEN, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a significant expansion of company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements.

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...

Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone

SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450 participants have joined the...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

ALAMEDA, Calif., July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBlood

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers